Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland

INTRODUCTION: Venetoclax in combination with rituximab (VEN + R) demonstrated prolonged overall survival (OS) and progression-free survival (PFS) for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in comparison to standard chemoimmunotherapy [bendamustine + rituximab (BR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbier, Michaela, Durno, Nicholas, Bennison, Craig, Örtli, Mathias, Knapp, Christian, Schwenkglenks, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170651/
https://www.ncbi.nlm.nih.gov/pubmed/34757508
http://dx.doi.org/10.1007/s10198-021-01398-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170651/
https://www.ncbi.nlm.nih.gov/pubmed/34757508
http://dx.doi.org/10.1007/s10198-021-01398-7

Ejemplares similares